First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)

Tony Mok; Dong-Wan Kim; Yi-Long Wu; Benjamin J. Solomon; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Jennifer Tursi; Fiona Helen Blackhall

doi:10.1200/jco.2014.32.15_suppl.8002

First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8002 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8002-8002 ◽

Cited By ~ 29

Author(s):

Tony Mok ◽

Dong-Wan Kim ◽

Yi-Long Wu ◽

Benjamin J. Solomon ◽

Kazuhiko Nakagawa ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

Alk Positive

Download Full-text

MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX)

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2016.11.427 ◽

2017 ◽

Vol 12 (1) ◽

pp. S378-S379 ◽

Cited By ~ 4

Author(s):

Young Kim ◽

Toyoaki Hida ◽

Hiroshi Nokihara ◽

Masashi Kondo ◽

Koichi Azuma ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Phase Iii Study ◽

Alk Positive

Download Full-text

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000366 ◽

2015 ◽

Vol 10 (1) ◽

pp. 134-142 ◽

Cited By ~ 75

Author(s):

Ralph G. Zinner ◽

Coleman K. Obasaju ◽

David R. Spigel ◽

Robert W. Weaver ◽

J. Thaddeus Beck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study

Download Full-text

PD4-2-3: Global Lung Oncology Branch trial 3 (Glob 3): final results of a randomised multinational Phase III study of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283381.78585.f2 ◽

2007 ◽

Vol 2 (8) ◽

pp. S451

Author(s):

Eng-Huat Tan ◽

Tomasz Grodzki ◽

Claus-Peter Schneider ◽

Peter Zatloukal ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.

10.1158/1538-7445.sabcs18-ct074 ◽

2019 ◽

Cited By ~ 3

Author(s):

Solange Peters ◽

Byoung Chul Cho ◽

Niels Reinmuth ◽

Ki Hyeong Lee ◽

Alexander Luft ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Mutational Burden ◽

Tumor Mutational Burden ◽

Phase Iii Study

Download Full-text

Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer--data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyv054 ◽

2015 ◽

Vol 45 (7) ◽

pp. 670-676 ◽

Cited By ~ 16

Author(s):

E. Miyauchi ◽

A. Inoue ◽

K. Kobayashi ◽

M. Maemondo ◽

S. Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Cancer Data ◽

Phase Iii Study

Download Full-text

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdn774 ◽

2009 ◽

Vol 20 (7) ◽

pp. 1249-1256 ◽

Cited By ~ 43

Author(s):

E.H. Tan ◽

J. Rolski ◽

T. Grodzki ◽

C.P. Schneider ◽

U. Gatzemeier ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

A Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin in First Line Non-Squamous Non-Small Cell Lung Cancer (Nsq-Nsclc)

Annals of Oncology ◽

10.1093/annonc/mdu438.49 ◽

2014 ◽

Vol 25 ◽

pp. v1 ◽

Cited By ~ 1

Author(s):

Y. Kim ◽

I. Oh ◽

K. Kim ◽

T. Jang ◽

Y.D. Choi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study

Download Full-text

EXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1093/annonc/mdx091.066 ◽

2017 ◽

Vol 28 ◽

pp. ii51

Author(s):

L. Horn ◽

Y.-L. Wu ◽

M. Reck ◽

C. Liang ◽

F. Tan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Phase Iii Study ◽

Alk Positive

Download Full-text

P-452 Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender

Lung Cancer ◽

10.1016/s0169-5002(05)80945-6 ◽

2005 ◽

Vol 49 ◽

pp. S235 ◽

Cited By ~ 9

Author(s):

C. Belani ◽

J. von Pawel ◽

A. Pluzanska ◽

V. Gorbounova ◽

E. Kaukel ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007)

Annals of Oncology ◽

10.1016/s0923-7534(20)34338-6 ◽

2012 ◽

Vol 23 ◽

pp. ixe21 ◽

Cited By ~ 25

Author(s):

A.T. Shaw ◽

D.W. Kim ◽

K. Nakagawa ◽

T. Seto ◽

L. Crinò ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Phase Iii Study ◽

Alk Positive ◽

Docetaxel Chemotherapy

Download Full-text